Advanced Search

 

Study ID Status Title Patient Level Data
201367 Completed Meta-Analysis Plan for 201367, Additional Analysis of Two Multicenter Trials Comparing the Efficacy and Safety of GSK573719/GW642444 with GSK573719, GW642444 and Tiotropium over 24 weeks in Subjects with COPD
201373 Completed Characterization of patients with Chronic Lymphocytic Leukemia in British Columbia, Canada using a province-wide CLL database
201378 Completed A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist
201379 Active, Not Recruiting Patterns of Care for Patients with Metastatic Renal Cell Carcinoma in a United States Population
201390 Active, Not Recruiting Impact of Disease Activity on Mortality and Damage Progression in Systemic Lupus Erythematosus (SLE) Patients with Active Disease despite Standard of Care in the Toronto Lupus Cohort
201393 Completed PGx7572: An Exploratory Investigation of CYP2D6 Activity and Efficacy of tafenoquine and primaquine in TAF112582 Part 1
201398 Completed An Exploratory Meta-Analysis of the Efficacy of Dolutegravir across Subgroups
201402 Completed A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions Study Listed on ClinicalStudyDataRequest.com
201426 Completed PRJ2250: Survey of patient and prescriber understanding of risks associated with TROBALT
201435 Completed A randomised, multi-centre, open label, cross-over non-inferiority study to evaluate efficacy, safety and tolerability of Neumoterol 400 and Symbicort Forte in adults with asthma
201450 Not yet recruiting ENCRUSE ELLIPTA Drug Use Investigation
201463 Completed Measurement of neutrophil retention in the lung in vivo, using autologous labelled neutrophils, in healthy subjects following lipopolysaccharide or saline challenge and patients with chronic obstructive pulmonary disease (COPD)
201465 Completed A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test
201474 Completed A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
201477 Completed Duration of Protection Following Five Doses of GlaxoSmithKline’s (GSK’s) DTaP Vaccines in School Age Children
201479 Completed A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects
201486 Completed PGX6475: PGx evaluation of HLA alleles with rash in lapatinib treated patients from TEACH (EGF105485)
201490 Completed PGx7591: Pharmacogenetic Evaluation of HLA effect on safety events in systemic lupus erythematosus patients treated with GSK2586184 in study JAK115919
201510 Completed An observer-blind study to assess the safety, reactogenicity and immunogenicity of different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), in healthy women
201512 Active, Not Recruiting Clinical and economic outcomes associated with use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium as initial maintenance treatment for chronic obstructive pulmonary disease in a managed care setting
201514 Active, Not Recruiting Impact of initiating maintenance treatment (MT) promptly post-chronic obstructive pulmonary disease (COPD) exacerbation in a managed care setting
201527 Completed Comparative Randomized, Single dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt)and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a Single Oral Dose Administration of each to Healthy Adults under Fasting Conditions
201528 Completed Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Raperazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a single oral dose administration of each to healthy adults under fed conditions
201529 Completed Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil from Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions Study Listed on ClinicalStudyDataRequest.com
201530 Active, Not Recruiting Qualitative Feasibility of Patient-Centered Mixed-Methods Analysis of SLE Patient Experience Trajectories: The BLISS Trials

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.